Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Short Interest Update

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) was the target of a large drop in short interest in the month of January. As of January 31st, there was short interest totalling 723,200 shares, a drop of 47.2% from the January 15th total of 1,370,000 shares. Approximately 4.2% of the company’s stock are short sold. Based on an average daily volume of 9,280,000 shares, the short-interest ratio is currently 0.1 days.

Insider Buying and Selling at Syros Pharmaceuticals

In other Syros Pharmaceuticals news, Director Nancy A. Simonian sold 134,713 shares of the firm’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $0.27, for a total transaction of $36,372.51. Following the transaction, the director now owns 41,070 shares of the company’s stock, valued at approximately $11,088.90. This trade represents a 76.64 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 12.26% of the company’s stock.

Hedge Funds Weigh In On Syros Pharmaceuticals

An institutional investor recently bought a new position in Syros Pharmaceuticals stock. GSA Capital Partners LLP purchased a new position in shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 15,905 shares of the company’s stock, valued at approximately $34,000. GSA Capital Partners LLP owned about 0.06% of Syros Pharmaceuticals as of its most recent SEC filing. 91.47% of the stock is currently owned by hedge funds and other institutional investors.

Syros Pharmaceuticals Stock Down 3.9 %

Syros Pharmaceuticals stock traded down $0.01 during mid-day trading on Thursday, hitting $0.18. The company had a trading volume of 535,137 shares, compared to its average volume of 1,647,263. The stock has a market cap of $4.75 million, a price-to-earnings ratio of -0.06 and a beta of 1.29. Syros Pharmaceuticals has a 1 year low of $0.16 and a 1 year high of $7.96. The business has a fifty day moving average of $0.21 and a 200 day moving average of $1.43.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. StockNews.com assumed coverage on shares of Syros Pharmaceuticals in a research note on Sunday. They issued a “sell” rating for the company. Brookline Capital Management reaffirmed a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. TD Cowen reissued a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. JMP Securities restated a “market perform” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. Finally, HC Wainwright restated a “neutral” rating and set a $1.00 target price (down from $6.00) on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $3.33.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.